CTIS2024-513191-17-00招募中1 期
API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patient who provided free, written and informed consent, Patient aged = 18 years, Patient with a diagnosis of primary or secondary autoimmune hemolytic anemia (AIHA) (infections, hematologic diseases, systemic diseases), according to the following criteria: - Hemoglobin <12 g/dL - and decreased haptoglobin (<0,4 g/L) - and positive direct antiglobulin test (direct Coombs test) (IgG +/- C3d), Newly diagnosed or relapsed patient (relapse is defined as a decrease in basal hemoglobin in association with AIHA - thus meeting the above criteria: Hb <12 g/dl and haptoglobin <0.4 g/L and IgG-positive TDA with or without C3d - and for whom the investigator deems it necessary to initiate etiological treatment specific to AIHA), Patient with an estimated life expectancy of more than 6 months
排除标准
- •Patients with immediate symptomatic VTE, confirmed by appropriate complementary examinations (venous Doppler of the lower limbs, thoracic CT angiography or pulmonary scintigraphy)., Patients with a contraindication to enoxaparin: - hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low-molecular-weight heparins (LMWH), or to any of the excipients, - history of heparin-induced thrombocytopenia, Patient with cold agglutinin-related AIHA (C3d-positive ADT alone with identification of cold agglutinins), Patient with severe hemostasis disorders: - hypofibrinogenemia < 2 g/L, - disseminated intravascular coagulation (APTT prolongation >1.2, and PT <50%, and thrombocytopenia <100 G/L, and D-Dimer >500 µg/L) - hemophilia, Patient whose clinical condition requires hospitalization in an intensive care unit, Patient who has already participated in the study, Patient not affiliated to national health insurance, Patient under legal protection (curatorship, guardianship), Patient subject to a court order, Pregnant, parturient or breastfeeding women, Patient with physiological capacity to procreate (having had her first menstrual period and not menopausal and not presenting permanent sterility (hysterectomy, bilateral salpingectomy, bilateral oophorectomy)) and unable to have effective contraception (i.e., provided by an estrogenprogestin oral contraceptive or progestogen, a contraceptive implant, an intrauterine device or a tubal ligation), Patients on curative anticoagulation (VTE, atrial fibrillation), Patient of legal age who is unable to provide consent, Patient on dual antiplatelet treatment, Patient with active bleeding, Patient with a known condition or lesion at risk of bleeding, Patient with ischemic stroke with hemorrhagic transformation within 6 months prior to inclusion, Patient on preventive anticoagulation for 14 days or more, Patient with a contraindication to apixaban: - Known hypersensitivity to the molecule or to any of the excipients, - thrombocytopenia <100 G/L, - kidney failure (glomerular filtration rate < 30 ml/min/1.73m²), - Active liver disease (liver failure defined as Factor V <50% or INR >1.5, ALT elevation >2 times the upper limit of normal), Patients receiving concomitant treatment with potent CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's wort) or potent CYP3A4 inhibitors (azole antifungals, HIV protease inhibitors), if these treatments cannot be discontinued or modified.
研究者
相似试验
尚未招募
不适用
Randomized, Evaluation of LoNg-term Anticoagulation with Oral Factor Xa Inhibitor versus Vitamin K Antagonist after Mechanical AorTic Valve ReplacEmentKCT0005315Asan Medical Center1,300
尚未招募
3 期
Effectiveness and safety of blood thinning agent (Anticoagulation) in patients with dying limb with poor blood supply (Digital Gangrene) and an underlying immune system related disease (Connective Tissue Disease)CTRI/2024/03/063481Department of Clinical Immunology & Rheumatology
已完成
不适用
Efficacy and safety of anticoagulant treatment using new alternative antithrombotic agents in acute cardioembolic stroke with nonvalvular atrial fibrillation.cerebral infarctionJPRN-UMIN000010477Department of Neurology, Kansai Medical University50
招募中
不适用
Efficacy and safety of anticoagulant treatment using New oral anticoagulant (edoxaban) in atrial fibrillation after cardiac surgery.arterial fibrillation after cardiac surgery (nonvalvular disease)JPRN-UMIN000021138ihon University school of medicine150
尚未招募
不适用
The efficacy and safety of anticoagulant therapy Arixtra Injection for the prevention of the vein thromboembolism in laparoscopic colorectal surgerycolorectal cancerJPRN-UMIN000007005Osaka Medical College200